Long-acting
beta2-agonists are bronchodilators, a class of asthma medication,
taken on a daily basis to relax the smooth muscle lining of bronchial
tubes, the airways that carry air to the lungs. It allows the tubes
to stay open for a longer period of time to help breathe easily. Long
acting beta2-agonists are used to open narrow airways and prevent
asthma attacks. These are used in dry powder or metered-dose
inhalers. According to the FDA guidelines, long acting beta2-agonists
should not be used without being combined with inhaled
corticosteroid. Examples of inhaled steroids are Qvar, Flovent,
Budesonide, Azmacort, Asmanex, and Aerobid. The most commonly
prescribed long acting beta2-agonists are Salmeterol (Serevent),
Formoterol (Foradil and Perforomist), and Arformoterol (Brovana).
Report Overview @
https://www.transparencymarketresearch.com/long-acting-beta2agonists-drugs-market.html
Long acting
beta2-agonists are considered primary drugs of choice to control
chronic asthma and chronic obstructive pulmonary disease (COPD), as
these make breathing easier. The usage of long acting beta2-agonists
in adults with persistent asthma results in improved lung function.
Increasing the dose of inhaled corticosteroids results in less use of
quick-relief medicines and improves lung function and symptoms.
Ability of the drug
to control asthma and rise in the population suffering from asthma
and chronic diseases such as COPD are expected to drive the global
long acting beta2-agonists drugs market. According to the World
Health organization (WHO), in 2015, nearly 383,000 people died due to
asthma. Many asthma-related deaths occur in low- and lower-middle
income countries. It also stated that approximately 235 million
people are presently suffering from asthma and it is a common disease
among children.
Download Report
Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33878
Moreover, in 2015,
chronic obstructive pulmonary disease accounted for 3 million deaths
across the world, approximately 5% of all the deaths. The primary
cause of chronic obstructive pulmonary disease is exposure to tobacco
smoke, either passive or active. The market is expected to expand due
to popularity of and preference for long acting beta2-agonists drugs.
However, patent and exclusivity expiry of top selling drugs such as
Serevent is likely to restrain the global market. The global long
acting beta2-agonists drugs market can be segmented based on
application, distribution channel, and region. In terms of
application, the market can be categorized into asthma and chronic
obstructive pulmonary disease (COPD). Based on distribution channel,
the global long acting beta2-agonists drugs market can be classified
into hospital pharmacies, retail pharmacies, and online pharmacies.
Geographically, the
global long acting beta2-agonists drugs market can be segmented into
Asia Pacific, Latin America, Europe, North America, and Middle East &
Africa. North America held the largest market share in 2016 owing to
increase in prevalence of asthma and chronic obstructive pulmonary
disease. COPD is the third leading cause of death in the U.S.
According to the Centers for Disease Control and Prevention (CDC),
nearly 6.4% i.e., 15.7 million, people in the U.S. reported that they
had been diagnosed with chronic obstructive pulmonary disease. CDC
also stated that nearly 18.4 million people, 7.6% of the total
population, aged 18 years and above in the U.S. currently suffer from
asthma. Europe accounted for the second largest market share in 2016
owing to increase in prevalence of asthma. According to Asthma U.K.,
nearly 5.4 million people in the U.K., 1.1 million children (1 in 11)
and 4.3 million adults (1 in 12), are currently diagnosed with
asthma. The market in Asia Pacific, Latin America, and Middle East &
Africa is anticipated to expand during the forecast period owing to
increasing population and air pollution.
Pre-Book Full
Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=33878<ype=S
Key players
operating in the global long acting beta2-agonists drugs market
include AstraZeneca, Teva Pharmaceutical Industries Ltd., Bayer AG,
Actelion Pharmaceuticals US, Inc. Boehringer Ingelheim GmbH, F.
Hoffmann-La Roche Ltd., and GlaxoSmithKline plc.
About Us
Transparency Market
Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive
edge.
Each TMR syndicated
research report covers a different sector - such as pharmaceuticals,
chemicals, energy, food & beverages, semiconductors, med-devices,
consumer goods and technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider
scope and stratified research methodology, TMR’s syndicated reports
strive to provide clients to serve their overall research
requirement.
US Office
Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel:
+1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment